Acrongenomics and Molecular Vision: Fully Functional Multi-Channel Prototype Device...

Acrongenomics and Molecular Vision: Fully Functional Multi-Channel Prototype Device Undergoing Internal Validation

GENEVA--(Business Wire)--
Acrongenomics Inc. (AGNM: OTCBB), today announces that it is fully
committed to the joint collaboration contract in partnership with
Molecular Vision.

Molecular Vision states that the latest iteration of the
technology is currently being tested as part of the on-going research
and development agreement. In one simple step, the fully functional,
multi-channel device will be used to simultaneously measure both
Creatinine and Vitamin C directly from a urine sample. It is
anticipated that this device will be presented to an external audience
in the coming weeks.

Furthermore progress continues to be made in the detection of
myoglobin, a cardiac biomarker. In keeping with the development
timelines this assay will be tested with human blood samples in the
near future, reaching another milestone in the evolution of this
proprietary detection technology.

About Acrongenomics:

Acrongenomics Inc. is a publicly traded company that focuses on
investing in and commercializing novel technology platforms concerning
the Life Sciences sector. Acrongenomics brings novel and realistic
concepts to market by transforming scientific innovations into
tangible, consumer-orientated applications. The company has its
headquarters in Geneva, Switzerland.

About Molecular Vision:

Molecular Vision is an Imperial College spin-out company that
develops low-cost diagnostic devices for use in the doctor's surgery
and in the home. Its proprietary devices combine microfluidic chips
with organic-semiconductor light-sources and photodetectors to provide
lab-quality diagnostic tests in a miniaturised, easy-to-use,
disposable format.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements
of historical facts are forward-looking statements which contain our
current expectations about our future results. Forward-looking
statements involve numerous risks and uncertainties. We have attempted
to identify any forward- looking statements by using words such as
"anticipates", "believes", "could", "expects", "intends", "may",
"should" and other similar expressions. Although we believe that the
expectations reflected in all of our forward looking statements are
reasonable, we can give no assurance that such expectations will prove
to be correct. A number of factors may affect our future results and
may cause those results to differ materially from those indicated in
any forward-looking statements made by us or on our behalf. Such
factors include our limited operating history; our need for
significant capital to finance internal growth as well as strategic
acquisitions; our ability to attract and retain key employees and
strategic partners; our ability to achieve and maintain profitability;
fluctuations in the trading price and volume of our stock; competition
from other providers of similar products and services; and other
unanticipated future events and conditions. For further information
concerning risks and uncertainties that may affect our future results,
please review the disclosures contained in our latest filings with the
SEC, including our most recent annual report on Form 10-KSB, and
subsequent quarterly reports on Form 10-QSB. Other than as required by
federal securities laws, we undertake no obligation to publicly update
or revise any of our forward- looking statements, whether as a result
of changed circumstances, new information, future events, or for any
other reason occurring after the date of this news release.

Acrongenomics Inc.
Dr. Dimitri Goundis, Chief Executive Officer,
+41 22 716 5300
Fax: +41 22 716 5319

Copyright Business Wire 2008